Paired comparison of methylene blue‐ and amotosalen‐treated plasma and cryoprecipitate

Cryoprecipitate is used in the treatment of patients with acquired hypofibrinogenaemia. Studies have not directly compared cryoprecipitate produced following pathogen inactivation (PI) of fresh‐frozen plasma (FFP) using different systems. The effects of methylene blue (MB) and amotosalen (AS) PI systems on the quality of FFP and cryoprecipitate were investigated in a paired study.

[1]  Jason P Acker,et al.  Quality Assessment of Established and Emerging Blood Components for Transfusion , 2016, Journal of blood transfusion.

[2]  C. Prowse,et al.  Pathogen inactivation or pathogen reduction: proposal for standardization of nomenclature , 2015, Transfusion.

[3]  V. Compernolle,et al.  Paired analysis of plasma proteins and coagulant capacity after treatment with three methods of pathogen reduction , 2014, Transfusion.

[4]  U. Martinowitz,et al.  In vitro evaluation of clot quality and stability in a model of severe thrombocytopenia: effect of fibrinogen, factor XIII and thrombin-activatable fibrinolysis inhibitor. , 2014, Blood transfusion = Trasfusione del sangue.

[5]  C. Prowse,et al.  Component pathogen inactivation: a critical review , 2013, Vox sanguinis.

[6]  M. Díaz-Ricart,et al.  Quantitative and qualitative analysis of coagulation factors in cryoprecipitate prepared from fresh‐frozen plasma inactivated with amotosalen and ultraviolet A light , 2013, Transfusion.

[7]  S. Stanworth,et al.  Cryoprecipitate: an outmoded treatment? , 2012, Transfusion medicine.

[8]  R. Benjamin,et al.  Plasma components: properties, differences, and uses , 2012, Transfusion.

[9]  G. Rock.  A comparison of methods of pathogen inactivation of FFP , 2011, Vox sanguinis.

[10]  Lily Lin,et al.  Pathogen Inactivation of Platelet and Plasma Blood Components for Transfusion Using the INTERCEPT Blood SystemTM , 2011, Transfusion Medicine and Hemotherapy.

[11]  L. Green,et al.  The effect of prion reduction in solvent/detergent‐treated plasma on haemostatic variables , 2010, Vox sanguinis.

[12]  R. Cardigan,et al.  Thrombin generation and clot formation in methylene blue–treated plasma and cryoprecipitate , 2009, Transfusion.

[13]  J. Cid,et al.  Quantitative and qualitative analysis of proteins in fresh frozen plasma obtained from whole blood donations and prepared with two photochemical treatments. , 2008, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[14]  J. Seghatchian,et al.  Updates on pathogen inactivation of plasma using Theraflex methylene blue system. , 2008, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[15]  R. Cardigan,et al.  The dynamics of clot formation in fresh‐frozen plasma , 2008, Vox sanguinis.

[16]  B. Châtelain,et al.  Coagulation function in fresh‐frozen plasma prepared with two photochemical treatment methods: methylene blue and amotosalen , 2007, Transfusion.

[17]  J. Loscalzo,et al.  Factor XIII (FXIII) and angiogenesis , 2006, Journal of thrombosis and haemostasis : JTH.

[18]  M. Blombäck,et al.  Changes in functional activities of plasma fibrinogen after treatment with methylene blue and red light , 2003, Transfusion.

[19]  C. Prowse,et al.  Cryoprecipitate prepared from methylene blue‐treated fresh plasma , 2001, Transfusion.

[20]  C. Prowse,et al.  Coagulation factor content of cryoprecipitate prepared from methylene blue plus light virus‐inactivated plasma , 2000, British journal of haematology.

[21]  J. Aznar,et al.  Clotting factors in cryoprecipitate and cryo‐supernatant prepared from MB‐treated fresh plasma , 2000, Transfusion.

[22]  M. Carr,et al.  Methylene blue enhances lateral association of fibrin resulting in rapid gelation and thick fiber formation. , 1989, Thrombosis and haemostasis.